Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2020

01-02-2020 | Positron Emission Tomography | Original Article

Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain

Authors: Vasko Kramer, Agnete Dyssegaard, Jonathan Flores, Cristian Soza-Ried, Frank Rösch, Gitte Moos Knudsen, Horacio Amaral, Matthias M. Herth

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2020

Login to get access

Abstract

Purpose

The serotonin receptor subtype 2A antagonist (5-HT2AR) (R)-[18F]MH.MZ has in preclinical studies been identified as a promising PET imaging agent for quantification of cerebral 5-HT2ARs. It displays a very similar selectivity profile as [11C]MDL 100907, one of the most selective compounds identified thus far for the 5-HT2AR. As [11C]MDL 100907, (R)-[18F]MH.MZ also displays slow brain kinetics in various animal models; however, the half-life of fluorine-18 allows for long scan times and consequently, a more precise determination of 5-HT2AR binding could still be feasible. In this study, we aimed to evaluate the potential of (R)-[18F]MH.MZ PET to image and quantify the 5-HT2AR in the human brain in vivo.

Methods

Nine healthy volunteers underwent (R)-[18F]MH.MZ PET at baseline and four out of these also received a second PET scan, after ketanserin pretreatment. Regional time–activity curves of 17 brain regions were analyzed before and after pretreatment. We also investigated radiometabolism, time-dependent stability of outcomes measures, specificity of (R)-[18F]MH.MZ 5-HT2AR binding, and performance of different kinetic modeling approaches.

Results

Highest uptake was determined in 5-HT2AR rich regions with a BPND of approximately 1.5 in cortex regions. No radiometabolism was observed. 1TCM and 2TCM resulted in similar outcome measure, whereas reference tissue models resulted in a small, but predictable bias. (R)-[18F]MH.MZ binding conformed to the known distribution of 5-HT2AR and could be blocked by pretreatment with ketanserin. Moreover, outcomes measures were stable after 100–110 min.

Conclusion

(R)-[18F]MH.MZ is a suitable PET tracer to image and quantify the 5-HT2AR system in humans. In comparison with [11C]MDL 100907, faster and more precise outcome measure could be obtained using (R)-[18F]MH.MZ. We believe that (R)-[18F]MH.MZ has the potential to become the antagonist radiotracer of choice to investigate the human 5-HT2AR system.
Appendix
Available only for authorised users
Literature
1.
Naughton M, Mulrooney JB, Leonard BE. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol Clin Exp. 2000;15(6):397–415.
2.
Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5):1614–41.PubMed
3.
4.
Gonzalez-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32(4):225–32.PubMed
5.
Piel M, Vernaleken I, Rosch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57(22):9232–58.PubMed
6.
Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9(6):633–43.PubMed
7.
Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14(50):1–103.PubMed
8.
Kristensen JL, Herth MM. Textbook of drug design and discovery: in vivo imaging in drug discovery. Fifth edition ed 2017.
9.
Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab. 2010;30(10):1682–706.PubMedPubMedCentral
10.
Skinbjerg M, Sibley DR, Javitch JA, Abi-Dargham A. Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction? Biochem Pharmacol. 2012;83(2):193–8.PubMed
11.
Ettrup A, da Cunha-Bang S, McMahon B, Lehel S, Dyssegaard A, Skibsted AW, et al. Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36. J Cereb Blood Flow Metab. 2014;34(7):1188–96.PubMedPubMedCentral
12.
Herth MM, Knudsen GM. Current radiosynthesis strategies for 5-HT2A receptor PET tracers. J Label Compd Radiopharm. 2015;58(7):265–73.
13.
Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, et al. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100907 measured by positron emission tomography. Neuropsychopharmacology. 1997;17(3):175–85.PubMed
14.
Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. 2013;33(1):54–111.PubMed
15.
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019.
16.
Stenbaek DS, Kristiansen S, Burmester D, Madsen MK, Frokjaer VG, Knudsen GM, et al. Trait openness and serotonin 2A receptors in healthy volunteers: a positron emission tomography study. Hum Brain Mapp 2019.
17.
Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther. 1996;277(2):968–81.PubMed
18.
Herth MM, Kramer V, Piel M, Palner M, Riss PJ, Knudsen GM, et al. Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009;17(8):2989–3002.PubMed
19.
Leysen JE. Use of 5-ht receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton A, Baker G, Juorio A, editors. Drugs as tools in neurotransmitter research. Neuromethods. 12: Humana Press; 1989. p. 299–350.
20.
Bhagwagar Z, Hinz R, Taylor M, Fancy S, Cowen P, Grasby P. Increased 5-HT2A receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [11C]MDL 100,907. Am J Psychiatry. 2006;163(9):1580–7.PubMed
21.
Hirani E, Sharp T, Sprakes M, Grasby P, Hume S. Fenfluramine evokes 5-HT2A receptor-mediated responses but does not displace [11C]MDL 100907: small animal PET and gene expression studies. Synapse. 2003;50(3):251–60.PubMed
22.
Ito H, Nyberg S, Halldin C, Lundkvist C, Farde L. PET imaging of central 5-HT2A receptors with [11C]MDL 100907. J Nucl Med. 1998;39(1):208–14.PubMed
23.
Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, et al. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100907. J Cereb Blood Flow Metab. 2000;20(6):899–909.PubMed
24.
Talvik-Lotfi M, Nyberg S, Nordstrom AL, Ito H, Halldin C, Brunner F, et al. High 5-HT2A receptor occupancy in MDL 100907 treated schizophrenic patients. Psychopharmacology. 2000;148(4):400–3.PubMed
25.
Pinborg LH, Adams KH, Svarer C, Holm S, Hasselbalch SG, Haugbol S, et al. Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab. 2003;23(8):985–96.PubMed
26.
Talbot PS, Slifstein M, Hwang DR, Huang Y, Scher E, Abi-Dargham A, et al. Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer [11C]MDL 100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone. Neuroimage. 2012;59(1):271–85.PubMed
27.
Meyer PT, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM, Hinz R. Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100907 PET and non-invasive kinetic analyses. Neuroimage. 2010;50(3):984–93.PubMed
28.
Hinz R, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM. Validation of a tracer kinetic model for the quantification of 5-HT2A receptors in human brain with [11C]MDL 100907. J Cereb Blood Flow Metab. 2007;27(1):161–72.PubMed
29.
Hall H, Farde L, Halldin C, Lundkvist C, Sedvall G. Autoradiographic localization of 5-HT2A receptors in the human brain using [3H]MDL 100907 and [11C]MDL 100907. Synapse. 2000;38(4):421–31.PubMed
30.
Debus F, Herth MM, Piel M, Buchholz HG, Bausbacher N, Kramer V, et al. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging. Nucl Med Biol. 2010;37(4):487–95.PubMed
31.
Hansen HD, Ettrup A, Herth MM, Dyssegaard A, Ratner C, Gillings N, et al. Direct comparison of [18F]MH.MZ and [18F]altanserin for 5-HT2A receptor imaging with PET. Synapse. 2013;67(6):328–37.PubMed
32.
Herth MM, Piel M, Debus F, Schmitt U, Luddens H, Rosch F. Preliminary in vivo and ex vivo evaluation of the 5-HT2A imaging probe [18F]MH.MZ. Nucl Med Biol. 2009;36(4):447–54.PubMed
33.
Herth MM, Debus F, Piel M, Palner M, Knudsen GM, Luddens H, et al. Total synthesis and evaluation of [18F]MH.MZ. Bioorg Med Chem Lett. 2008;18(4):1515–9.PubMed
34.
Herth MM, Kramer V, Gillings N, Rösch F, Knudsen GM. Direct radiofluorination of [18F]MH.MZ for 5-HT2A receptor molecular imaging with PET. J Label Compd Radiopharm. 2012;55(9):354–8.
35.
Abi-Dargham A, Martinez D, Mawlawi O, Simpson N, Hwang DR, Slifstein M, et al. Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab. 2000;20(2):225–43.PubMed
36.
Gillings N. A restricted access material for rapid analysis of 11C-labeled radiopharmaceuticals and their metabolites in plasma. Nucl Med Biol. 2009;36(8):961–5.PubMed
37.
Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–47.
38.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533–9.PubMed
39.
Schmidt KC, Turkheimer FE. Kinetic modeling in positron emission tomography. Q J Nucl Med. 2002;46(1):70–85.PubMed
40.
Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 1985;346(2):231–49.PubMed
41.
Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A. 1997;94(10):5308–13.PubMedPubMedCentral
42.
Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbol S, et al. A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage. 2004;21(3):1105–13.PubMed
43.
Horsager J, Munk OL, Sorensen M. Metabolic liver function measured in vivo by dynamic 18F-FDGal PET/CT without arterial blood sampling. EJNMMI Res. 2015;5:32–7.PubMedPubMedCentral
44.
Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, et al. Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls. J Cereb Blood Flow Metab. 1995;15(5):787–97.PubMed
45.
Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, et al. [11C]MDL 100907, a radioligland for selective imaging of 5-HT2A receptors with positron emission tomography. Life Sci. 1996;58(10):PL 187–92.
Metadata
Title
Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain
Authors
Vasko Kramer
Agnete Dyssegaard
Jonathan Flores
Cristian Soza-Ried
Frank Rösch
Gitte Moos Knudsen
Horacio Amaral
Matthias M. Herth
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04527-w

Other articles of this Issue 2/2020

European Journal of Nuclear Medicine and Molecular Imaging 2/2020 Go to the issue

Editorial

Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer’s disease: why it is time to abandon the approach

Society Communications

EANM Springer Prizes awarded at EANM’ 19 Barcelona

Letter to the Editor

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET”

Publisher Correction

Publisher Correction: Artificial intelligence and radiomics in nuclear medicine: potentials and challenges

Original Article

In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography

Editorial

A future for PET imaging in Alzheimer’s disease